PROFOUND MEDICAL CORP. financials

PROF CIK 0001628808

Source: EDGAR filings · Built 2026-09-24T01:16:45Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -38.38M — — — -22.39M —
EBITDA -40.69M -32.13M -27.72M -30.52M -28.41M -17.32M
Working Capital 70.01M 62.50M 35.53M — — —
Net Debt -55.01M -49.79M -18.35M -38.29M -65.78M -82.24M
Gross Margin 70.77% 72.25% 73.10% — — —
Operating Margin -256.27% -339.45% -485.69% -480.86% -440.72% -258.26%
Net Margin -264.44% -285.59% -480.13% -429.11% -446.66% -296.03%
Return on Equity (ROE) -64.08% -46.04% -90.71% -54.51% -38.08% -22.21%
Return on Assets (ROA) -54.95% -39.60% -64.43% — — —
Current Ratio 12.52× 10.52× 6.58× — — —
Debt-to-Equity 0.07× 0.08× 0.25× 0.16× 0.02× 0.02×
Effective Tax Rate -0.60% 0.01% 0.45% — — —
Cash Conversion Ratio 0.90× 0.84× 0.80× 0.90× 0.73× 0.95×
Accruals Ratio -0.06× -0.06× -0.13× — — —
SBC % of Revenue 34.10% 26.50% 57.93% — — —
CapEx Coverage -217.09× — — — -698.75× —
Free Cash Flow Per Share $-1.27 — — — — —

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax — 9.74M 5.90M — — —
Revenues 16.10M 10.68M 7.20M — — —
Cost of Revenue 4.71M 3.64M 2.89M — — —
Gross Profit 11.39M 7.04M 4.31M — — —
Research and Development Expense 20.60M 16.96M 14.42M — — —
Selling, General and Administrative Expense 32.05M 23.13M 18.54M — — —
Operating Expenses 52.65M 40.10M 32.96M — — —
Operating Income (Loss) -41.25M -33.06M -28.65M — — —
Income Tax Expense (Benefit) 252.00K -2.00K -128.00K — — —
Net Income (Loss) Attributable to Parent -42.57M -27.82M -28.32M — — —
Earnings Per Share, Basic $1.41 $1.12 $1.34 — — —
Weighted Average Number of Shares Outstanding, Basic 30.23M 24.77M 21.18M — — —
Earnings Per Share, Diluted $1.41 $1.12 $1.34 — — —
Weighted Average Number of Shares Outstanding, Diluted 30.23M 24.77M 21.18M — — —

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 59.72M 54.91M 26.21M — — —
Assets, Current 76.09M 69.06M 41.90M — — —
Assets 77.47M 70.23M 43.96M — — —
Long-term Debt 4.50M 4.66M 7.10M 7.17M — —
Liabilities, Current 6.08M 6.57M 6.37M — — —
Long-term Debt, Excluding Current Maturities 4.50M 2.92M 5.00M — — —
Liabilities 11.04M 9.81M 12.73M — — —
Stockholders' Equity Attributable to Parent 66.43M 60.42M 31.22M 52.60M — —
Common Stock, Shares, Outstanding 36.29M 30.04M 21.37M — — —

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -38.21M -23.45M -22.61M — — —
Payments to Acquire Property, Plant, and Equipment 176.00K — — — — —
Net Cash Provided by (Used in) Investing Activities -242.00K — — — — —
Net Cash Provided by (Used in) Financing Activities 41.14M 54.70M 1.76M — — —

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PROF CIK 0001628808), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

HCM

HutchMED (China) LIMITED

RCAT

Red Cat Holdings, Inc.

ASTS

AST SPACEMOBILE, INC.